Biovail Exits U.S. Primary Care Market; Narrows Focus To Specialty Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
In an attempt to boost profitability, Biovail will divest its Teveten franchise to Kos, which will also gain distribution rights for Cardizem LA. The $104 mil. deal also includes an R&D collaboration for three products in Biovail's cardiovascular product pipeline.
You may also be interested in...
Kos' Sales Force To Reach 700 Reps Under Biovail Deal
Kos' sales force will grow roughly 27% to 700 reps with the addition of approximately 150 Biovail primary care reps under an agreement announced May 3
Kos' Sales Force To Reach 700 Reps Under Biovail Deal
Kos' sales force will grow roughly 27% to 700 reps with the addition of approximately 150 Biovail primary care reps under an agreement announced May 3
Biovail/Depomed’s Glumetza “Approvable” For Type II Diabetes
Approval of once-daily, extended-release metformin awaits completion of discussions on manufacturing specifications. FDA’s letter does not cite clinical, GMP or labeling issues, the companies say.